Session » Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 1032

Anti-arthritogenic Effect of Smoking in Curdlan-Administered SKG Mice

9:00AM-10:30AM: Abstract Number: 1023

Are We Treating-to-target in Spondyloarthritis (SpA)? A Cross Sectional Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry

9:00AM-10:30AM: Abstract Number: 1019

Association Between Stringent Clinical Measures of Disease Activity and Clinically Meaningful Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: Results from KEEPsAKE 1 and 2 Clinical Trials

9:00AM-10:30AM: Abstract Number: 1016

Cardiovascular Disease Proteome Profile Is Related to an Abnormal Methylome Pattern in Spondyloarthritis: Potential Biomarkers of Subclinical Atherosclerosis

9:00AM-10:30AM: Abstract Number: 1018

Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study

9:00AM-10:30AM: Abstract Number: 1034

Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice

9:00AM-10:30AM: Abstract Number: 1010

Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies

9:00AM-10:30AM: Abstract Number: 1012

Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Arthritis: Results of the CASIPSA Study

9:00AM-10:30AM: Abstract Number: 1021

Depression as a Modulator of Patient Reported, but Not Physician Observed, Outcomes in Psoriatic Arthritis

9:00AM-10:30AM: Abstract Number: 1030

Diagnostic Usefulness of Anti-PPM1A-IgM in Patients with Ankylosing Spondylitis

9:00AM-10:30AM: Abstract Number: 1013

Discriminatory Capacity of the ASAS Health Index in Patients with Axial Spondyloarthritis Treated in a Tight Control Setting versus Standard of Care

9:00AM-10:30AM: Abstract Number: 1009

Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial

9:00AM-10:30AM: Abstract Number: 1008

Endothelial Dysfunction in Axial Spondyloarthritis and Its Association with Clinical Disease Characteristics

9:00AM-10:30AM: Abstract Number: 1025

Entheseal Biopsy Approach: An Ultrasound-guided Method for Retrieval of Entheseal Tissue from Psoriatic Arthritis Patients

9:00AM-10:30AM: Abstract Number: 1031

Foot Involvement in Psoriatic Arthritis- a Retrospective Study

9:00AM-10:30AM: Abstract Number: 1028

How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?

9:00AM-10:30AM: Abstract Number: 1006

Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies

9:00AM-10:30AM: Abstract Number: 1005

Increasing the Proficiency for Scoring Sacroiliac Joint Radiographs According to the Modified New York Criteria for Ankylosing Spondylitis by Using an Online Real-time Iterative Calibration (RETIC) Module

9:00AM-10:30AM: Abstract Number: 1014

Is Radiographic Axial Involvement Associated with Syndesmophyte Development After 2 Years in PsA Patients?

9:00AM-10:30AM: Abstract Number: 1027

Low Dose Computed Tomography Hounsfield Units: A Reliable Methodology for Assessing Changes in Vertebral Bone Density in Radiographic Axial Spondyloarthritis

9:00AM-10:30AM: Abstract Number: 1007

Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study

9:00AM-10:30AM: Abstract Number: 1017

Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies

9:00AM-10:30AM: Abstract Number: 1024

Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance

9:00AM-10:30AM: Abstract Number: 1015

Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial

9:00AM-10:30AM: Abstract Number: 1026

Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis

9:00AM-10:30AM: Abstract Number: 1033

Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort

9:00AM-10:30AM: Abstract Number: 1020

Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review

9:00AM-10:30AM: Abstract Number: 1004

SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis

9:00AM-10:30AM: Abstract Number: 1011

Trends in Fracture Rates Among Veterans with Ankylosing Spondylitis

9:00AM-10:30AM: Abstract Number: 1022

Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis

9:00AM-10:30AM: Abstract Number: 1029

Virtual Assessment in Axial Spondyloarthritis: Validation of Video Observation of Spinal Metrology

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].